Autonomix Enhances Government Management Workforce with Appointment of Confirmed Medical Expertise Chief, Brad Hauser, as President and Chief Government Officer

Former President and Chief Government Officer, Lori Bisson, appointed as Government Vice Chairman

THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Firm”), a medical system firm centered on advancing progressive applied sciences to revolutionize how ailments involving the nervous system are recognized and handled, in the present day introduced adjustments to its government management staff to help its subsequent pivotal part of growth. Efficient instantly, Brad Hauser has been appointed as President and Chief Government Officer. Moreover, Lori Bisson, former President and Chief Government Officer, has been appointed Government Vice Chairman of the Board and can proceed to information the Firm ahead on company and capital markets methods.

Mr. Hauser is a globally famend medical expertise innovation chief and seasoned government with greater than 20 years of expertise constructing groups that carry distinctive energy-based applied sciences from idea, by means of design validation, medical research, regulatory approvals, manufacturing, and commercialization. Over the course of his profession, he has been a visionary for high laser, radiofrequency, sound and chilly applied sciences treating a broad vary of indications from vascular to adipose tissue to pores and skin. Beforehand, he was a part of the groups that efficiently took three corporations by means of acquisition, Soliton, Inc., ZELTIQ Aesthetics, and Reliant Applied sciences, and has been an officer of 4 public corporations.

“We’re extraordinarily grateful for Lori’s transformational efforts in establishing the strong basis from which the Firm is now positioned to propel in direction of our subsequent part of development,” commented Walter Klemp, Government Chairman of Autonomix. “We’re happy to welcome Brad to the chief management staff and wholeheartedly consider his experience and confirmed monitor document instantly brings important worth to the Firm.”

Ms. Lori Bisson said, “A number of of our staff members and I’ve had the pleasure of working with Brad at a previous firm and his management fashion is an ideal match for the subsequent part of Autonomix’s growth. Particularly, his prior intensive expertise with tissue coagulation and ablation methods brings a big worth and profitable monitor document, along with his historical past of mixing medical and regulatory growth with product manufacturing and launch, which really makes him the best candidate and optimum time for this subsequent step in our Firm’s development. We’re all thrilled to be working with him once more.”

Mr. Hauser added, “I couldn’t be extra excited by this chance and to staff up once more with these confirmed leaders to fill an necessary unmet want for sufferers and their households with the objective of constructing important worth for our shareholders. I’ve spent the vast majority of my profession working carefully with physicians and partnering with them to advance novel applied sciences and I consider that Autonomix has the potential to remodel affected person outcomes and revolutionize how ailments involving the nervous system are recognized and handled. The preclinical and preliminary proof of idea knowledge are extremely compelling, and we’ll proceed to expeditiously advance our medical program in an effort to search regulatory approvals globally.”

About Brad Hauser

Mr. Hauser joins Autonomix having most just lately served because the Chief Working Officer at Magnificence Well being, a worldwide category-creating firm delivering tens of millions of pores and skin well being experiences yearly. Whereas at Magnificence Well being, he led operations, advertising, expertise, analysis and growth, high quality assurance and regulatory affairs and oversaw product growth with a concentrate on persevering with to advance the HydraFacial supply methods and pioneer innovation.

Previous to his appointment at Magnificence Well being, Mr. Hauser served as President and Chief Government Officer at Soliton, the place he led the RESONIC model from early business launch by means of acquisition by Allergan Aesthetics, an AbbVie firm, for $550M enterprise worth in 2021. Following the acquisition, he served as President and Chief Government Officer at Soliton inside Allergan Aesthetics, an AbbVie firm till July 2022. Previous to that, he served in a number of roles at ZELTIQ Aesthetics, Inc. together with Vice President of Product and Medical Technique, Vice President of Analysis and Improvement and Senior Vice President of Analysis and Improvement, the place he helped construct the CoolSculpting franchise from a $100M to $350M+ world enterprise over 4 years and a sale to Allergan for $2.4B in 2017. Following the acquisition, his position elevated additional to function Vice President, R&D and Normal Supervisor for the Coolsculpting and Physique Contouring portfolio at Allergan Prescribed drugs. Previous to ZELTIQ, Mr. Hauser held a number of roles within the aesthetic trade, together with Government Vice President of Industrial Operations for Cutera, Director of Analysis and Improvement at Medicis and Managing Director of Product and Medical Advertising and marketing at Solta Medical. He at present sits on the Board of Administrators of Candesant Biomedical and the American Society of Laser Medication and Surgical procedure, Inc. (ASLMS). Mr. Hauser holds a Bachelor of Arts in Human Biology from Stanford College.

Inducement Grant

In reference to Mr. Hauser becoming a member of Autonomix, the Compensation Committee of Autonomix’s Board of Administrators authorized the grant of an inducement inventory choice to be granted on June 17, 2024, to buy 900,000 shares of the Firm’s frequent inventory. The choice award was granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a element of the person’s employment compensation and was granted as an inducement materials to his acceptance of employment with Autonomix.

The choice has an train worth equal to the closing worth of Autonomix’s frequent inventory as reported by the Nasdaq Capital Market on June 17, 2024. The choices have a ten-year time period and vest in 4 equal annual installments, topic to Mr. Hauser’s continued service with Autonomix by means of the relevant vesting dates.

About Autonomix Medical, Inc.

Autonomix is a medical system firm centered on advancing progressive applied sciences to revolutionize how ailments involving the nervous system are recognized and handled. The Firm’s first-in-class expertise platform features a catheter-based microchip sensing array that has the power to detect and differentiate neural alerts with roughly 3,000 occasions larger sensitivity than at present accessible applied sciences. We consider this may allow, for the primary time ever, transvascular analysis and therapy of ailments involving the peripheral nervous system nearly anyplace within the physique.

We’re initially growing expertise for ache, with our first medical trial specializing in pancreatic most cancers, a situation that causes debilitating ache and is with out an efficient resolution. Our expertise constitutes a platform to deal with dozens of indications, together with cardiology, hypertension and persistent ache administration, throughout a large illness spectrum.

For extra data, go to autonomix.com and join with the Firm on X, LinkedIn, Instagram and Fb.

Ahead Trying Statements

Among the statements on this launch are “forward-looking statements,” which contain dangers and uncertainties. Such forward-looking statements could be recognized by way of phrases resembling “ought to,” “may,” “could,” “intends,” “anticipates,” “believes,” “estimates,” “tasks,” “forecasts,” “expects,” “plans,” and “proposes.”

Though Autonomix believes that the expectations mirrored in these forward-looking statements are based mostly on affordable assumptions, there are a variety of dangers and uncertainties that would trigger precise outcomes to vary materially from such forward-looking statements. You might be urged to rigorously evaluate and contemplate any cautionary statements and different disclosures, together with the statements made below the heading “Danger Components” and elsewhere within the Annual Report on Kind 10-Ok filed with the U.S. Securities and Change Fee (“SEC”) on Could 31, 2024. Ahead-looking statements converse solely as of the date of the doc wherein they’re contained and Autonomix doesn’t undertake any obligation to replace any forward-looking statements besides as could also be required by regulation.

Investor and Media Contact

JTC Workforce, LLC

Jenene Thomas

833-475-8247

autonomix@jtcir.com

Attachment



Primary Logo

Autonomix Medical, Inc.

Mr. Hauser

Leave a Comment